Use of aerosolized aminoglycosides in the treatment of gram-negative ventilator-associated pneumonia

Surgical Infections

Volumn 8, Issue 3, 2007, Pages 349-357

  Mohr, Alicia M ^a   Sifri, Ziad C ^a   Horng, Helen S ^a   Sadek, Ragui ^a   Savetamal, Alisa ^a   Hauser, Carl J ^a   Livingston, David H ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; IMIPENEM; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TOBRAMYCIN;

ADD ON THERAPY; ADULT; AEROSOL; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL VIRULENCE; BRONCHOSCOPY; BRONCHOSPASM; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MEDICAL RECORD; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPUTUM CULTURE; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR; VENTILATOR ASSOCIATED PNEUMONIA;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; NEW JERSEY; PNEUMONIA, VENTILATOR-ASSOCIATED; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34547494491     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.041     Document Type: Conference Paper

References (34)

1. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
2. Lesho E. Role of inhaled antibacterials in hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect 2005;3:445-451.
3. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Dis 2002;142:523-528.
4. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003;290:2588-2598.
5. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imepenem-cilastatin. Antimicrob Agents Chemother 1994;38:547-557.
6. Rello J, Mariscal D, March F, et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: Relapse or reinfection? Am J Respir Crit Care Med 1998;157:912-916.
7. Wood GC, Boucher BA. Aerosolized antimicrobial therapy in acutely ill patients. Pharmacotherapy 2000; 20:166-181.
8. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006;43:S89-S94.
9. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymixins for the treatment of infections in critically ill patients: A review of the recent literature. Clin Med Res 2006;4:138-146.
10. Montero A, Corbella X, Ariza J. Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia. Crit Care Med 2003;31:2557-2559.
11. Ryan G, Mukhopadhyay S, Stingh M. Nebulised antipseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003;3:CD001021.
12. Pino G, Conterno G, Colongo PG. Clinical observations on the activity of aerosol colimycin and of endobronchial instillations of colimycin in patients with pulmonary suppurations. Minerva Med 1963;54: 2117-2122.
13. O'Riordan T, Faris M. Inhaled antimicrobial therapy. Respir Care Clin North Am 1999;5:617-631.
14. Stoutenbeek CP, van Saene HKF, Miranda DR, et al. Nosocomial gram-negative penumonia in critically ill patients: A 3-year experience with a novel therapeutic regimen. Intensive Care Med 1986;12:419-423.
15. Michalopoulos A, Jasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-R59.
16. Smaldone GC, Palmer LB. Aerosolized antibiotics: Current and future. Respir Care 2000;45:667-675.
17. Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: Delivery and response. Crit Care Med 1998; 26:31-39.
18. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987;136:1445-1449.
19. LeConte P, Potel G, Peltier P, et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993;147:1279-1282.
20. Cooney GF, Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994;34:255-259.
21. Touw DJ, Jacobs FAH, Brimicombe RW, et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41:184-187.
22. McCall CY, Spruill WJ, Wade WE. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonia. Ther Drug Monit 1989;11: 692-695.
23. LeConte P, Potel G, Clementi E, et al. Administration of tobramycin aerosols in patients with nosocomial pneumonia: A preliminary study. Presse Med 2000; 29:76-78.
24. Drobnic ME, Sune P, Montoro JB, et al. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005;39: 39-44.
25. Smaldone GC. Aerosolized antibiotics in mechanically ventilated patients. Resp Care 2004;49:635-639.
26. Klastersky J, Huysmans E, Weerts D, et al. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: A double-blind study. Chest 1974;65: 650-654.
27. Levine BA, Petroff PA, Slade CL, Pruitt BA. Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. J Trauma 1978;18:188-193.
28. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
29. Goldstein I, Wallet F, Robert J, et al. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002;165:171-175.
30. Faurisson F, Dessanges JF, Grimfeld A, et al. Nebulizer performance: AFLM study. Respiration 1995;62: 13-18.
31. Hung JC, Hambleton G, Super M. Evaluation of two commercial jet nebulizers and three compressors for the nebulization of antibiotics. Arch Dis Child 1994;71:335-338.
32. LeBrun PP, deBoer AH, Marines GP, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy 2: Inhalation of a novel colistin dry powder formulation: A feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm 2002;54:25-32.
33. Bressolle F, de la Coussaye JE, Ayoub R, et al. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: Pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992;36:1404-1411.
34. Lake KB, Van Dyke JJ, Rumsfeld JA. Combined topical pulmonary and systemic gentamicin: The question of safety. Chest 1975;68:62-64.